My new article is about the revolutionary work of John Weir Perry, the leading Jungian in the area of compassionate treatment of extreme states. I completed the follow-up research on his Diabasis House. It was a medication-free program for young adults going through extreme states/psychosis. We were close friends and colleagues for many years, until John’s death in 1998.
In this new video, Dr. Peter Breggin and I discuss with Dr. Ken Castleman, the frightening new Monarch eTNS electric brain device being prescribed for use all night long on children diagnosed with ADHD. Ken is a Biomedical Engineer who taught at Cal-Tech and has served on NASA’s space shuttle program. He is very concerned about the effects of the Monarch’s sustained electric current on the vulnerable, developing brains of children. At one point, Ken said, “I know how electricity works, and what it does to human tissue.” I believe he does.
I co-authored this brief article with good friend Dr. Peter Breggin, about the new international advocacy project we’re starting called “Stop the Psychiatric Abuse of Children” (SPAC!). Please join us in spreading the alert about the new children’s Monarch eTNS electrical brain device approved by the FDA, and in opposing all the psychiatric harm done to children that we document in our article.
Michael Cornwall, PhD
Director – SPAC!
I’ll be serving as director for a new activism project called “Stop the Psychiatric Abuse of Children” or SPAC, as described in Peter Breggin’s article at Mad in America.
Peter and I will be publicly launching the SPAC project on his Progressive Radio Network (PRN.FM) program on Wednesday, June 12, 2019, at 4:00 PM EST. Please join us on the air with your calls (888-874-4888).
I’ll be leading this upcoming weekend workshop at Esalen Institute with my friend, Dr. David Lukoff, on January 27-29, 2017. Since 2011, I’ve organized and co-led six week-long or weekend workshops at Esalen, all aimed at a group exploration of expanding our understanding of extreme states, and the development of enhanced ways to compassionately respond to people in extreme states.
My new article on Mad in America about the price we all pay for our universal and core needs for empathy, compassion and love not being met in our wasteland culture.
In this new article I sound the alarm on an ominous shift in how psychosis is diagnosed, that will use a system of bio-marker tests to label people in extreme states as being in a psychosis biotype group.
This entry first appeared at Mad In America on November 10, 2015.
I felt a chill go through my body when I read that the FDA has agreed to review for possible approval in early 2016 a new form of the drug Abilify that contains a microchip sensor capable of sending a message that indicates the exact time a tablet dissolves in the stomach. The message is recorded by a skin patch – along with data such as the person’s body angle and activity patterns – and, according to a press release from Proteus Digital Health, the developer of the device, “this information is recorded and relayed to patients on a mobile phone or other Bluetooth-enabled device, and only with their consent, to their physician and/or their caregivers.”
The Japanese drug giant Otsuka teamed up with Proteus Digital Health in 2012 to create this potentially profitable new “chip in a pill” just as its patent on Abilify – at $6.9 billion the #1 most profitable drug in the U.S. in 2013 – was set to expire in 2014, leaving one of Otsuka’s most valuable markets vulnerable to generics. It is especially ominous to me that our government is teetering toward passing the Murphy Bill, which would make forced in-home treatment the law of the land, at the same time it is lurching toward putting such an Orwellian device in the hands of a pharmaceutical company, courts, and families.
According to the Washington Examiner:
”The new smart drug could be particularly useful for ensuring the mentally ill continue taking their medications, not just by giving doctors a way to monitor their behavior, but courts as well…all but five states have court-ordered programs where a judge can mandate that offenders with severe mental illness stick with a treatment program as a condition of remaining in the community.”
As one Facebook commenter noted; putting a pill in your mouth and swallowing it, knowing it’s going to transmit a message to prove one is submissive and compliant, is beyond Orwellian – it feels fascistic. I agree. The social contract draws an invisible line that must be guarded against forces in a society that, driven by fears, fantasies of benevolence, or by simple greed, and are blind and deaf to the cries of its citizens as their bodily and personal integrity are ground into powder along with the preparations they are compelled to take in the specious name of “health” and “safety.”
Sometimes, radicalizing people politically takes a really callous, stupid, and dangerous threat to people’s liberty. This is one of those times.
The Washington Examiner article cites recent research that shows 74% of people who are started on antipsychotic medications stop taking them within 18 months. That’s the justification offered for a psych drug that monitors its own use.
“These individuals already have a history of problems due to their unwillingness or inability to voluntarily comply with treatment … this could be an important advance for them that would help them maintain treatment compliance.”
— D.J. Jaffe of the Mental Illness Policy Org.
Think about it: faced with the overwhelming 74% failure of a pharmaceutical intervention, why is the core issue deemed to be compliance rather than efficacy, and consumers’ safety & satisfaction? And why are we “gearing up” to ensure compliance in particular for a drug that even the FDA admits has an unknown mechanism of action?
What other medical specialty would blame its patients for so overwhelmingly choosing not to take the medications that have been prescribed to them? For a field that has taken on the charge of controlling and regulating social deviance, the ethical boundaries that the FDA should be protecting are blurred by the growing perception that people who are DSM-diagnosed are potential risks to society, despite overwhelming risk to the contrary; that a DSM diagnoses should be a signal that a person needs and deserves our protection.
Only a worldview that embraces the disease and deviance model of human emotional suffering would dare to suggest putting a sensor in a psychoactive substance to monitor and enforce its ingestion by an otherwise free citizen.
I believe that at some very basic level empathy seems to have failed in a society that sees the need to develop a sensor-equipped psychoactive substance. The blasé emphasis on prioritizing prescription compliance, without considering the profound subjective experience – to anyone, let alone a person in crisis – of having a digitalized foreign object inserted deep inside, an object that is in turn sending messages to an invisible outside presence. This oversight amounts to a vertiginous stumble forward in our society’s failure to muster empathy and compassion for its members, instead delivering them, in the form of a now-literally captive market, to the drug makers.
I’ve been seeing clients in therapy for over 35 years, and at no point can I imagine sitting a few feet away from a person in distress and suggest to them that they should consider having a device inside them that would let me know every day at a distance their most intimate experiences – let alone when they digest something, lie down, or when they have taken their meds. I couldn’t do it. It would feel ghoulish and perverse.
And I don’t want to be a part of a society that would do. Even – and perhaps especially – if it were being done “in my name.”
There is an aura of something shameful, a violation of a basic human right to privacy and bodily boundaries that is being ignored in the pursuit of this new digital monitoring of psychiatric medication. The shame is that, with a pill that records the moment of its absorption into our bodies, we are seeing the realization of a long-sought ideal of totalitarian governments; to cross the blood-brain barrier, gaining access to the very seat of our autonomy, and of our souls. With this, Otsuka could fairly revamp its marketing for Abilify by renaming it “Dis-Abilify,” without so much as risking – and potentially augmenting, in a society that seems to be exuberantly embracing an Orwellian ideal – its market share.
This is a time, if there ever was one, for citizens to act, and to act decisively; before the ability to make decisions, let alone act on them, is excised from our bodies completely by the next wave of pharma development.
Of course some will object to my characterization of those who developed this seeming well-meaning medical breakthrough as lacking a moral compass. But I have already heard the cries of outrage and fear from many of those for whom this Orwellian medicine is intended.
I’ll end here with an ever-more apt quote from C.S. Lewis –
“Of all tyrannies, a tyranny sincerely exercised for the good of its victims, may be the most oppressive.”
A brief new article here about mental health providers who believe they never could suffer in the ways many of the people they serve experience, and how that belief limits the provider’s capacity for empathy and compassion.